Clinical Trials Logo

Clinical Trial Summary

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023. Research hypothesis: Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06238219
Study type Observational
Source Erasme University Hospital
Contact Denis Schmartz, MD
Phone +3225553919
Email denis.schmartz@hubruxelles.be
Status Recruiting
Phase
Start date April 17, 2024
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02880787 - Comparison of Two Neuromuscular Transmission Monitors Based on Acceleromyography: TOF-Watch SX® and TOFScan® N/A
Completed NCT03804346 - Infantile - Postoperative Residual Curarization - Study
Completed NCT02630576 - Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy (Volunteers N/A
Completed NCT02711917 - Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane N/A
Terminated NCT03778749 - Electromyography and Acceleromyography in Ventilated ICU Patients N/A
Completed NCT02350062 - Comparison of Two Neuromuscular Monitors N/A
Recruiting NCT03605225 - Development and Validation of an Android-based Application for Anaesthesia Neuromuscular Monitoring N/A
Completed NCT02025309 - Intraoperative Methylprednisolone and Sugammadex Phase 4
Completed NCT04947306 - A Comparison Between TOF Watch® SX and Tetragraph®